Lipase inhibitors
View Patent ↗The present invention provides lipase inhibitors containing flavan-3-ol monomers or acylates thereof derived from teas as well as foods and beverages and medicines containing said inhibitors. More specifically, the present invention provides lipase inhibitors containing at least one of flavan-3-ol monomers represented by the formula: wherein R 1 and R 3 independently represent H or OH, R 2 represents H, R 4 represents H, G, 3MeG or p-cou, R 5 represents H or G, R 4 ′ and R 5 ′ independently represent H or G, R 4 ″ represents H or G, and G, 3MeG and p-cou respectively represent the groups of the formulae: or acylates thereof; as well as foods and beverages and medicines containing said lipase inhibitors.
1. A method for suppressing absorption of dietary lipids and/or suppressing a rise of triglycerides in blood in a mammal comprising administering to the mammal a composition consisting essentially of at least one of the compounds represented by the formula:
wherein G is represented by the formula:
wherein the compound(s) is administered in a total amount effective to suppress absorption of dietary lipids and/or suppress a rise of triglycerides in blood in the mammal, and wherein the composition suppresses absorption of dietary lipids and/or suppresses a rise of triglycerides in blood in the mammal.
2. The method of claim 1 , wherein the composition containing at least (−)-epigallocatechin 3,5-di-O-gallate.
3. The method of claim 1 or 2 , wherein the composition contains at least one of the compounds in an amount of 0.1 mg or more per meal or 0.1 mg or more per dose.
4. The method of claim 3 , wherein the composition contains at least one of the compounds in an amount of 0.1 mg to 10 g per meal or 0.1 mg to 10 g per dose.
5. The method of claim 4 , wherein the composition is a food or beverage, or a pharmaceutical composition.
6. The method of claim 5 , wherein the composition is a food or beverage selected from the group consisting of tea drinks, soft drinks and health foods.
7. A method for inhibiting lipase activity in a mammal comprising administering to the mammal a composition consisting essentially of at least one of the compounds represented by the formula:
wherein G is represented by the formula:
wherein the compound(s) is administered in a total amount effective to inhibit lipase activity in the mammal, and wherein the composition inhibits lipase activity in the mammal.
8. The method of claim 7 , wherein the method comprises using at least (−)-epigallocatechin 3,5-di-O-gallate.
9. A method for treating a disease or condition ameliorated by administering a lipase inhibitory agent in a mammal comprising administering to the mammal a composition consisting essentially of at least one of the compounds represented by the formula:
wherein G is represented by the formula:
wherein the compound(s) is administered in a total amount effective to treat the disease or condition in the mammal, and wherein the disease or condition ameliorated by administering a lipase inhibitory agent is treated with the composition.
10. The method of claim 9 , wherein the composition containing at least (−)-epigallocatechin 3,5-di-O-gallate.
11. The method of claim 9 or 10 , wherein the disease or condition is one selected from the group consisting of obesity, diabetes, hyperlipidemia, hypertension, arteriosclerosis and hypertriglyceridemia.
12. A method of producing a food or beverage comprising using, as an ingredient in the food or beverage, a composition consisting essentially of at least one of the compounds represented by the formula:
wherein G is represented by the formula:
and wherein the compound(s) is included in a total amount effective to suppress absorption of dietary lipids and/or suppress a rise of triglycerides in blood in a mammal, thereby obtaining the food or beverage that has an ability to suppress absorption of dietary lipids and/or suppress a rise of triglycerides in blood in the mammal.
13. A method for suppressing absorption of dietary lipids and/or suppressing a rise of triglycerides in blood in a mammal comprising administering to the mammal at least one of the compounds represented by the formula:
wherein G is represented by the formula:
and wherein the compound(s) suppresses absorption of dietary lipids and/or suppresses a rise of triglycerides in the blood in the mammal.
14. The method of claim 13 , wherein the method comprises administering at least at least (−)-epigallocatechin 3,5-di-O-gallate.
15. The method of claim 13 or 14 , wherein the method comprises administering at least one of the compounds in an amount of 0.1 mg or more per meal or 0.1 mg or more per dose.
16. The method of claim 15 , wherein the method comprises administering at least one of the compounds in an amount of 0.1 mg to 10 g per meal or 0.1 mg to 10 g per dose.
17. The method of claim 13 , wherein at least one of the compounds is included in a food, a beverage, or a pharmaceutical composition.
18. The method of claim 17 , wherein the food or beverage is selected from the group consisting of tea drinks, soft drinks, and health foods.
19. A method for inhibiting lipase activity in a mammal comprising administering to the mammal at least one of the compounds represented by the formula:
wherein G is represented by the formula:
and wherein the compound(s) inhibits lipase activity in the mammal.
20. A method for treating a disease or condition ameliorated by administering a lipase inhibitory agent in a mammal comprising administering to the mammal at least one of the compounds represented by the formula:
wherein G is represented by the formula:
and wherein the disease or condition ameliorated by administering the lipase inhibitory agent is treated with the compound(s).
21. The method of claim 20 , wherein the disease or condition is one selected from the group consisting of obesity, diabetes, hyperlipidemia, hypertension, arteriosclerosis, and hypertriglyceridemia.
22. A method for suppressing absorption of dietary lipids and/or suppressing a rise of triglycerides in blood in a mammal in need thereof comprising administering to the mammal at least one of the compounds represented by the formula:
wherein G is represented by the formula:
and wherein the compound(s) suppresses absorption of dietary lipids and/or suppresses a rise of triglycerides in the blood in the mammal.